Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use

Respiratory Medicine

Volumn 107, Issue 2, 2013, Pages 223-232

  Decramer, Marc ^a   Dahl, Ronald ^b   Kornmann, Oliver ^c   Korn, Stephanie ^d   Lawrence, David ^e   McBryan, Danny ^f  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c IKF Pneumologie Frankfurt   (Germany)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

^e NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^f NOVARTIS PHARMA AG   (Switzerland)

Author keywords

COPD; Formoterol; Indacaterol; Salmeterol; Tiotropium

Indexed keywords

BRONCHODILATING AGENT; CORTICOSTEROID; FORMOTEROL; INDACATEROL; SALMETEROL; TIOTROPIUM BROMIDE;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT TOOL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMAN; LOWER RESPIRATORY TRACT INFECTION; META ANALYSIS; OPEN STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; RHINOPHARYNGITIS; ST GEORGE RESPIRATORY QUESTIONNAIRE; TRANSITION DYSPNEA INDEX; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; AGED; ALBUTEROL; BRONCHODILATOR AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DYSPNEA; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HUMANS; INDANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCOPOLAMINE DERIVATIVES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84872099048     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2012.10.022     Document Type: Article

References (35)

1. Global initiative for chronic obstructive lung disease (GOLD) Global strategy for diagnosis, management, and prevention of COPD 2011 At: www.goldcopd.org
2. G. Feldman, T. Siler, N. Prasad, D. Jack, S. Piggott, R. Owen INLIGHT 1 study group Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week study BMC Pulm Med 10 2010 11
3. 2-agonist indacaterol versus twice-daily formoterol in COPD Thorax 65 2010 473 479
4. J.F. Donohue, C. Fogarty, J. Lötvall, D.A. Mahler, H. Worth, A. Yorgancioglu INHANCE Study Investigators Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium Am J Respir Crit Care Med 182 2010 155 162
5. O. Kornmann, R. Dahl, S. Centanni, A. Dogra, R. Owen, and C. Lassen Once-daily indacaterol vs twice-daily salmeterol for COPD: a placebo-controlled comparison Eur Respir J 37 2011 273 279
6. M.R. Miller, J. Hankinson, V. Brusasco, F. Burgos, R. Casaburi, A. Coates ATS/ERS Task Force Standardization of spirometry Eur Respir J 26 2005 319 338
7. D.A. Mahler, D.H. Weinberg, C.K. Wells, and A.R. Feinstein The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes Chest 85 1984 751 758
8. T.J. Witek Jr., and D.A. Mahler Meaningful effect size and patterns of response of the transition dyspnea index J Clin Epidemiol 56 2003 248 255
9. T.J. Witek Jr., and D.A. Mahler Minimal important difference of the transition dyspnoea index in a multinational clinical trial Eur Respir J 21 2003 267 272
10. P.W. Jones, F.H. Quirk, C.M. Baveystock, and P. Littlejohns A self complete measure for chronic airflow limitation: the St George's Respiratory Questionnaire Am Rev Respir Dis 145 1992 1321 1327
11. P.W. Jones St. George's Respiratory Questionnaire: MCID COPD 2 2005 75 79
12. M. Decramer, B. Celli, S. Kesten, T. Lystig, S. Mehra, and D.P. Tashkin Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial Lancet 374 2009 1171 1178
13. C.R. Jenkins, P.W. Jones, P.M. Calverley, B. Celli, J.A. Anderson, and G.T. Ferguson Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study Respir Res 10 2009 59
14. C. Casanova, J.P. de Torres, A. Aguirre-Jaíme, V. Pinto-Plata, J.M. Marin, and E. Cordoba The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort Am J Respir Crit Care Med 184 2011 1015 1021
15. M. Decramer, and C.B. Cooper Treatment of COPD: the sooner the better? Thorax 65 2010 837 841
16. J. Vestbo, L.D. Edwards, P.D. Scanlon, J.C. Yates, A. Agusti, and P. Bakke Changes in forced expiratory volume in 1 second over time in COPD N Engl J Med 365 2011 1184 1192
17. B.R. Celli, C.G. Cote, J.M. Marin, C. Casanova, M. Montes de Oca, and R.A. Mendez The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease N Engl J Med 350 2004 1005 1012
18. M. Williams, P. Cafarella, T. Olds, J. Petkov, and P. Frith Affective descriptors of the sensation of breathlessness are more highly associated with severity of impairment than physical descriptors in people with COPD Chest 138 2010 315 322
19. M.T. Dransfield, W. Bailey, G. Crater, A. Emmett, D.M. O'Dell, and B. Yawn Disease severity and symptoms among patients receiving monotherapy for COPD Prim Care Respir J 20 2011 46 53
20. D. Renard, M. Looby, B. Kramer, D. Lawrence, D. Morris, and D.R. Stanski Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches Respir Res 12 2011 54
21. Meeting materials of the March 8, 2011, meeting of the Pulmonary-Allergy Drugs Advisory Committee, Food and Drug Administration. At: http://www.fda.gov/ downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ Pulmonary-AllergyDrugsAdvisoryCommittee/UCM248744.pdf [accessed 10.9.12].
22. Global initiative for chronic obstructive lung disease (GOLD) Global strategy for diagnosis, management, and prevention of COPD 2010 At: www.goldcopd.com
23. S. Suissa, and P.J. Barnes Inhaled corticosteroids in COPD: the case against Eur Respir J 34 2009 13 16
24. A. Jochmann, F. Neubauer, D. Miedinger, S. Schafroth, M. Tamm, and J.D. Leuppi General practitioner's adherence to the COPD GOLD guidelines: baseline data of the Swiss COPD Cohort Study Swiss Med Wkly 140 2010 w13053
25. G. Jebrak, and B.P.C.O. Initiatives COPD routine management in France: are guidelines used in clinical practice? Rev Mal Respir 27 2010 11 18
26. A.E. Lucas, F.W. Smeenk, I.J. Smeele, and C.P. van Schayck Overtreatment with inhaled corticosteroids and diagnostic problems in primary care patients, an exploratory study Fam Pract 25 2008 86 91
27. J. Bourbeau, R.J. Sebaldt, A. Day, J. Bouchard, A. Kaplan, and P. Hernandez Practice patterns in the management of chronic obstructive pulmonary disease in primary practice: the CAGE study Can Respir J 15 2008 13 19
28. K. Fitch, K. Iwasaki, B. Pyenson, C. Plauschinat, and J. Zhang Variation in adherence with Global Initiative for Chronic Obstructive Lung Disease (GOLD) drug therapy guidelines: a retrospective actuarial claims data analysis Curr Med Res Opin 27 2011 1425 1429
29. S. Suissa, R. McGhan, D. Niewoehner, and B. Make Inhaled corticosteroids in chronic obstructive pulmonary disease Proc Am Thorac Soc 4 2007 535 542
30. S. Singh, and Y.K. Loke An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease Int J Chron Obstruct Pulmon Dis 5 2010 189 195
31. P. Ernst, A.V. Gonzalez, P. Brassard, and S. Suissa Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia Am J Respir Crit Care Med 176 2007 162 166
32. P.M. Calverley, J.A. Anderson, B. Celli, G.T. Ferguson, C. Jenkins, P.W. Jones TORCH investigators Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease N Engl J Med 356 2007 775 789
33. J.A. Wedzicha, P.M. Calverley, T.A. Seemungal, G. Hagan, Z. Ansari, R.A. Stockley INSPIRE Investigators The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide Am J Respir Crit Care Med 177 2008 19 26
34. P. Kardos, M. Wencker, T. Glaab, and C. Vogelmeier Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease Am J Respir Crit Care Med 175 2007 144 149
35. M.B. Drummond, E.C. Dasenbrook, M.W. Pitz, D.J. Murphy, and E. Fan Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis JAMA 300 2008 2407 2416 Erratum in: JAMA 2009;301:1024